calcitriol
Trade name: rocaltrol
Approved
Aug 17, 1978
Calcitriol is a hormone and the active form of vitamin D, normally made in the kidney. It is also known as 1,25-dihydroxycholecalciferol. It binds to and activates the vitamin D receptor in the nucleus of the cell, which then increases the expression of many genes. Calcitriol increases blood calcium mainly by increasing the uptake of calcium from the intestines. — Wikipedia
Clinical trial activity
141 trials · 130 clinical orgs · 28 marketing orgs
Earliest trial started Mar 1, 1976 (NCT00001151)
Timeline
1970s
- Jan 1, 1976
Earliest Phase 2 Sponsor(trial)
- Aug 17, 1978
Validus Pharmaceuticals — Earliest FDA Approval
- Aug 17, 1978
Validus Pharmaceuticals — NDA Secondary Org
- Aug 17, 1978
Validus Pharmaceuticals — NDA Organization
- Aug 17, 1978
ESJAY PHARMA — Marketing Organization
1980s
- Sep 25, 1986
AbbVie — NDA Secondary Org
2000s
- Oct 12, 2001
Teva — Marketing Organization
- Dec 31, 2002
Hospira — Marketing Organization
- Feb 20, 2003
Fresenius — Marketing Organization
- Jul 18, 2003
West-Ward Pharmaceutical — Marketing Organization
- Jul 18, 2003
Hikma — Marketing Organization
- Sep 17, 2003
Rockwell Medical Inc — Marketing Organization
- Sep 26, 2003
Lutipold — Marketing Organization
- Sep 26, 2003
Sankyo — Marketing Organization
- Feb 8, 2006
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Jan 29, 2008
Akorn, Inc. — Marketing Organization
- Jan 29, 2008
LONG GROVE PHARMS — Marketing Organization
- Jan 23, 2009
Galderma — NDA Secondary Org
2010s
- May 24, 2013
Bionpharma Inc — Marketing Organization
- Dec 12, 2014
Strides Pharma Science — Marketing Organization
- Dec 12, 2014
ONESOURCE SPECIALTY — Marketing Organization
- Jun 14, 2017
Amneal Pharmaceuticals — Marketing Organization
- Nov 21, 2018
Invatech — Marketing Organization
- Nov 21, 2018
Elysium Health — Marketing Organization
- Nov 21, 2018
Rising Pharmaceuticals — Marketing Organization
- Feb 21, 2019
Sun Pharmaceuticals — Marketing Organization
- Oct 23, 2019
Gland Pharma Ltd — Marketing Organization
2020s
- Feb 3, 2020
Fosun — Marketing Organization
- Jul 28, 2023
Patrin Pharma Inc — Marketing Organization
- Jul 28, 2023
ANDA Repository — Marketing Organization
- Feb 27, 2026
Yichang Humanwell Pharmaceutical Co.,Ltd — Marketing Organization
Indications
Studied for
- Acute Febrile Encephalopathy · Early Phase 1
- Acute Kidney Injury · Phase 2
- Adenocarcinoma · Phase 1
- Alveolar Bone Loss · Phase 2
- Anemia · Phase 4
- Angiofibroma · Phase 3
- Asthma · Phase 4
- Attention Deficit Disorder with Hyperactivity · Phase 1
- Autoimmune Diseases · Phase 4
- Basal Cell Carcinoma · Phase 2
- Bone and Bones · Phase 2
- Bone Diseases, Metabolic · Phase 4
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cardio-Renal Syndrome · Phase 4
- Cholangiocarcinoma · Phase 2
- Chromosome Aberrations · Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 4
- Cocaine-Related Disorders · Early Phase 1
- Colorectal Neoplasms · Phase 1
- COVID-19 · Phase 2
- Critical Illness · Phase 2
- Crohn Disease · Phase 1/Phase 2
- Dermatitis, Atopic · Phase 2
- Diabetes Mellitus · Phase 1
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetic Nephropathies · Phase 4
- Dialysis · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Endometrial Neoplasms · Phase 1
- Familial Hypophosphatemic Rickets · Phase 4
- Fractures, Bone · Phase 2
- Friedreich Ataxia · Phase 4
- Glomerulonephritis · Phase 4
- Glomerulonephritis, IGA · Phase 4
- Hamartoma · Phase 1
- Healthy Volunteers · Phase 1
- Heart Transplantation · Phase 3
- Hemophilia A · Phase 1/Phase 2
- Hemophilia B · Phase 1/Phase 2
- Hypercalcemia · Phase 4
- Hyperparathyroidism, Secondary · Phase 4
- Hyperphosphatemia · Phase 4
- Hypertension · Phase 2
- Infertility, Male · Phase 2
- Insulin Resistance · Early Phase 1
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 2
- Klinefelter Syndrome · Phase 2
- Lupus Erythematosus, Systemic · Phase 4
- Malnutrition · Phase 4
- Melanoma · Phase 1/Phase 2
- Metabolism · Phase 4
- Mouth Neoplasms · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Nephritis · Phase 4
- Non-alcoholic Fatty Liver Disease · Phase 4
- Opioid-Related Disorders · Phase 1
- Osteopetrosis · Phase 3
- Osteoporosis · Phase 4
- Osteoporosis, Postmenopausal · Phase 4
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Pityriasis · Phase 4
- Precancerous Conditions · Phase 2
- Pregnancy Complications · Phase 2
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Proteinuria · Phase 4
- Purpura, Thrombocytopenic, Idiopathic · Phase 4
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Rickets · Phase 2
- Rickets, Hypophosphatemic · Early Phase 1
- Sepsis · Phase 2
- Thyroid Nodule · Phase 2
- Uterine Cervical Neoplasms · Phase 1
- Vascular Calcification · Phase 4
- Vascular Stiffness · Early Phase 1
- Vitamin D Deficiency · Phase 4
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Approval history
- approvedPriority reviewAug 17, 1978
Chemistry & pharmacology
SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C- Mol. weight
- 416.6365 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- WikipediaCalcitriol ↗
- NCATSFXC9231JVH ↗
- ChEMBLCHEMBL846 ↗
Also known as
- 1,25-dhcc
- 1,25-dhcc
- 1,25-dihydroxycholecalciferol
- 1,25-dihydroxycholecalciferol
- 1,25 dihydroxy vitamin d3
- 1,25 dihydroxy vitamin d3
- 1,25-dihydroxyvitamin d3
- 1alpha,25-dihydroxycholecalciferol
- 1alpha,25-dihydroxycholecalciferol
- 1-alpha-25-dihydroxyvitamin d3
- 1-alpha-25-dihydroxyvitamin d3
- 1alpha,25-dihydroxyvitamin d3
- 1alpha,25-dihydroxyvitamin d3
- (1s,3r,5z,7e)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
- (1s,3r,5z,7e)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
- 1α,25-dihydroxycholecalciferol
- 1α,25-dihydroxycholecalciferol
- 1α,25-dihydroxyvitamin d3
- 1α,25-dihydroxyvitamin d3
- 1α,25(oh)2d3
- 1α,25(oh)2d3
- (1α,3β,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
- (1α,3β,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
- (5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
- (5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
- calcijex
- calcijex
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriol
- calcitriolum
- calcitriolum
- calcitrol
- dihydroxycholecalciferol
- dihydroxycholecalciferol
- dihydroxyvitamin d3
- dihydroxyvitamin d 3
- ro-215535
- ro-215535
- rocaltrol
- rocaltrol
- rocaltrol
- rocaltrol
- rocaltrol
- rocaltrol
- rocaltrol
- silkis
- silkis
- topitriol
- topitriol
- topitriol
- vectical
- vectical
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07299552 | N/A | Dec 30, 2025 | Univerisiti Sains Malaysia |
| NCT07200349 | N/A | Nov 1, 2025 | Al Azhar University |
| NCT06261905 | Phase 1 | Mar 13, 2024 | University of Pennsylvania, Yale University |
| NCT06288451 | Phase 2 | Mar 11, 2024 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Washington |
| NCT06306131 | Phase 2 | Dec 10, 2023 | InnovaGyn, Inc., National Institutes of Health (NIH) |
| NCT06141239 | N/A | Dec 1, 2023 | Chang Gung University |
| NCT05902078 | Phase 4 | Jun 30, 2023 | Chugai, Jiao Tong University |
| NCT05720273 | Phase 4 | Apr 1, 2023 | Shandong Province Qianfoshan Hospital |
| NCT05601531 | N/A | Dec 1, 2022 | Chang Gung University |
| NCT05415254 | N/A | Jun 12, 2022 | Jiao Tong University |
| NCT05298163 | N/A | Apr 30, 2022 | University of Indonesia |
| NCT05920512 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2022 | People's Liberation Army of China |
| NCT04801303 | Phase 4 | Aug 25, 2021 | Institut de Recerca Biomèdica de Lleida, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Universitat de Lleida |
| NCT05765617 | Phase 2 | Jul 1, 2021 | Universitas Sebelas Maret |
| NCT04967469 | N/A | Sep 1, 2020 | Rajavithi Hospital, Bangkok |
| NCT04386811 | Phase 1 | May 31, 2020 | Yale University |
| NCT04286529 | Phase 1 | Mar 2, 2020 | Mayo Clinic |
| NCT05202496 | N/A | Nov 20, 2019 | Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences |
| NCT04094805 | Phase 4 | Oct 1, 2019 | Shandong University |
| NCT04826133 | Early Phase 1 (Phase 1) | Mar 27, 2019 | Yale University |
Organizations
Research & Development (130)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 12 | 0 | 3 | 1996 |
| Galderma | For profit | 10 | 9 | 3 | 2006 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 10 | 3 | 3 | 1976 |
| Novacea | For profit | 8 | 7 | 3 | 2002 |
| State University of New York, Buffalo | Academic/Hospital | 8 | 8 | 3 | 2002 |
| Harvard University | Academic/Hospital | 6 | 5 | 3 | 2009 |
| Abbott | For profit | 5 | 3 | 1 | 2003 |
| Oregon Health and Science University | Academic/Hospital | 5 | 4 | 2 | 1999 |
| Cornell University | Academic/Hospital | 4 | 2 | 2 | 1999 |
| Seoul National University | Academic/Hospital | 4 | 4 | 1 | 2012 |
| University of Pittsburgh | Academic/Hospital | 4 | 4 | 2 | 1996 |
| Department of Veteran Affairs | Government | 3 | 3 | 2 | 2007 |
| Merck | For profit | 3 | 2 | 3 | 1997 |
| National Institutes of Health (NIH) | Government | 3 | 1 | 1 | 1976 |
| Yale University | Academic/Hospital | 3 | 3 | 1 | 2019 |
| Aventis | For profit | 2 | 0 | 2 | 2002 |
| Boston University | Academic/Hospital | 2 | 0 | 1 | 1998 |
| Capital Medical University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Chang Gung University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Chinese University of Hong Kong | Academic/Hospital | 2 | 2 | 1 | 2006 |
Marketing (35)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Jul 28, 2023 |
| AbbVie | For profit | NDA2 | Sep 25, 1986 |
| Akorn, Inc. | For profit | MKTG | Jan 29, 2008 |
| Amneal Pharmaceuticals | For profit | MKTG | Jun 14, 2017 |
| Bionpharma Inc | For profit | MKTG | May 24, 2013 |
| Bionpharma Inc | For profit | SYN | May 24, 2013 |
| ESJAY PHARMA | For profit | MKTG | Aug 17, 1978 |
| Elysium Health | For profit | MKTG | Nov 21, 2018 |
| Fosun | For profit | MKTG | Feb 3, 2020 |
| Fresenius | For profit | SYN | Dec 31, 2002 |
| Fresenius | For profit | MKTG | Feb 20, 2003 |
| Galderma | For profit | NDA2 | Jan 23, 2009 |
| Gland Pharma Ltd | For profit | MKTG | Oct 23, 2019 |
| Gland Pharma Ltd | For profit | SYN | Feb 3, 2020 |
| Hikma | For profit | MKTG | Jul 18, 2003 |
| Hikma | For profit | SYN | Jul 18, 2003 |
| Hospira | For profit | MKTG | Dec 31, 2002 |
| Invatech | For profit | MKTG | Nov 21, 2018 |
| LONG GROVE PHARMS | For profit | MKTG | Jan 29, 2008 |
| Lutipold | For profit | MKTG | Sep 26, 2003 |
| ONESOURCE SPECIALTY | For profit | MKTG | Dec 12, 2014 |
| Patrin Pharma Inc | For profit | MKTG | Jul 28, 2023 |
| Rising Pharmaceuticals | For profit | MKTG | Nov 21, 2018 |
| Rockwell Medical Inc | For profit | MKTG | Sep 17, 2003 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Feb 8, 2006 |
| Sankyo | For profit | MKTG | Sep 26, 2003 |
| Strides Pharma Science | For profit | MKTG | Dec 12, 2014 |
| Sun Pharmaceuticals | For profit | MKTG | Feb 21, 2019 |
| Sun Pharmaceuticals | For profit | SYN | Feb 21, 2019 |
| Teva | For profit | MKTG | Oct 12, 2001 |
| Teva | For profit | SYN | Mar 31, 2003 |
| Validus Pharmaceuticals | For profit | NDA2 | Aug 17, 1978 |
| Validus Pharmaceuticals | For profit | NDA | Aug 17, 1978 |
| West-Ward Pharmaceutical | For profit | MKTG | Jul 18, 2003 |
| Yichang Humanwell Pharmaceutical Co.,Ltd | For profit | MKTG | Feb 27, 2026 |